Amylin Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: San Diego CA United States (1987)
Status: Acquired by Bristol-Myers Squibb (2012)

Organization Overview

First Clinical Trial
2002
NCT00044668
First Marketed Drug
2005
pramlintide (symlin)
First NDA Approval
2005
pramlintide (symlin)
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

AMYLIN | Amylin Pharmaceuticals, LLC.

Indications

Approved Indications


 

Diabetes Mellitus, Type 1

Diabetes Mellitus, Type 2

Lipodystrophy

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Body Weight (Phase 4)

Cardiovascular Diseases (Phase 4)

Diabetes Complications (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Fatty Liver (Phase 4)

Glucose Intolerance (Phase 4)

Heart Failure (Phase 2)

Hyperglycemia (Phase 4)

Hypoglycemia (Phase 2)

Infarction (Phase 4)

Insulin Resistance (Phase 4)

Lipodystrophy (Phase 2)

Liver Diseases (Phase 4)

Myocardial Infarction (Phase 4)

Non-alcoholic Fatty Liver Disease (Phase 4)

Obesity (Phase 2)

Overweight (Phase 2)

Polycystic Ovary Syndrome (Phase 2)

Prediabetic State (Phase 4)

Psychotic Disorders (Phase 4)

Schizophrenia (Phase 4)

Syndrome (Phase 2)

Weight Gain (Phase 4)

Weight Loss (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 61
  • # of Trial APIs: 20